Goodwill in USD of AVADEL PHARMACEUTICALS PLC from Q4 2011 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
Summary
AVADEL PHARMACEUTICALS PLC quarterly Goodwill history and change rate from Q4 2011 to Q3 2025.
  • AVADEL PHARMACEUTICALS PLC Goodwill for the quarter ending 30 Sep 2025 was $16.8M, unchanged year-over-year.
Goodwill, Quarterly (USD)
Goodwill, YoY Quarterly Change (%)

AVADEL PHARMACEUTICALS PLC Quarterly Goodwill (USD)

Period Value YoY Chg Change % Date Report Filed
Q3 2025 $16.8M $0 0% 30 Sep 2025 10-Q 04 Nov 2025
Q2 2025 $16.8M $0 0% 30 Jun 2025 10-Q 07 Aug 2025
Q1 2025 $16.8M $0 0% 31 Mar 2025 10-Q 07 May 2025
Q4 2024 $16.8M $0 0% 31 Dec 2024 10-Q 04 Nov 2025
Q3 2024 $16.8M $0 0% 30 Sep 2024 10-Q 12 Nov 2024
Q2 2024 $16.8M $0 0% 30 Jun 2024 10-Q 08 Aug 2024
Q1 2024 $16.8M $0 0% 31 Mar 2024 10-Q 08 May 2024
Q4 2023 $16.8M $0 0% 31 Dec 2023 10-K 03 Mar 2025
Q3 2023 $16.8M $0 0% 30 Sep 2023 10-Q 08 Nov 2023
Q2 2023 $16.8M $0 0% 30 Jun 2023 10-Q 09 Aug 2023
Q1 2023 $16.8M $0 0% 31 Mar 2023 10-Q 04 May 2023
Q4 2022 $16.8M $0 0% 31 Dec 2022 10-K 29 Feb 2024
Q3 2022 $16.8M $0 0% 30 Sep 2022 10-Q 09 Nov 2022
Q2 2022 $16.8M $0 0% 30 Jun 2022 10-Q 09 Aug 2022
Q1 2022 $16.8M $0 0% 31 Mar 2022 10-Q 09 May 2022
Q4 2021 $16.8M $0 0% 31 Dec 2021 10-K 29 Mar 2023
Q3 2021 $16.8M $0 0% 30 Sep 2021 10-Q 08 Nov 2021
Q2 2021 $16.8M $0 0% 30 Jun 2021 10-Q 09 Aug 2021
Q1 2021 $16.8M -$1.66M -8.95% 31 Mar 2021 10-Q 10 May 2021
Q4 2020 $16.8M -$1.66M -8.95% 31 Dec 2020 10-K 16 Mar 2022
Q3 2020 $16.8M -$1.66M -8.95% 30 Sep 2020 10-Q 09 Nov 2020
Q2 2020 $16.8M -$1.66M -8.95% 30 Jun 2020 10-Q 10 Aug 2020
Q1 2020 $18.5M $0 0% 31 Mar 2020 10-Q 11 May 2020
Q4 2019 $18.5M $0 0% 31 Dec 2019 10-K 09 Mar 2021
Q3 2019 $18.5M $0 0% 30 Sep 2019 10-Q 12 Nov 2019
Q2 2019 $18.5M $0 0% 30 Jun 2019 10-Q 09 Aug 2019
Q1 2019 $18.5M $0 0% 31 Mar 2019 10-Q 08 May 2019
Q4 2018 $18.5M $0 0% 31 Dec 2018 10-K 16 Mar 2020
Q3 2018 $18.5M $0 0% 30 Sep 2018 10-Q 05 Nov 2018
Q2 2018 $18.5M $0 0% 30 Jun 2018 10-Q 07 Aug 2018
Q1 2018 $18.5M $0 0% 31 Mar 2018 10-Q 04 May 2018
Q4 2017 $18.5M $0 0% 31 Dec 2017 10-K 15 Mar 2019
Q3 2017 $18.5M -$643K -3.36% 30 Sep 2017 10-Q 09 Nov 2017
Q2 2017 $18.5M -$178K -0.95% 30 Jun 2017 10-Q 09 Aug 2017
Q1 2017 $18.5M -$5.56M -23.1% 31 Mar 2017 10-Q 10 May 2017
Q4 2016 $18.5M $0 0% 31 Dec 2016 10-K 16 Mar 2018
Q3 2016 $19.1M 30 Sep 2016 10-Q 14 Nov 2016
Q2 2016 $18.7M +$178K +0.96% 30 Jun 2016 10-Q 15 Aug 2016
Q1 2016 $24.1M +$5.56M +30.1% 31 Mar 2016 10-Q 10 May 2016
Q4 2015 $18.5M $0 0% 31 Dec 2015 10-K 28 Mar 2017
Q2 2015 $18.5M $0 0% 30 Jun 2015 6-K 31 Dec 2015
Q1 2015 $18.5M $0 0% 31 Mar 2015 6-K 10 Jul 2015
Q4 2014 $18.5M $0 0% 31 Dec 2014 10-K 15 Mar 2016
Q3 2014 $18.5M $0 0% 30 Sep 2014 6-K 17 Nov 2014
Q2 2014 $18.5M $0 0% 30 Jun 2014 6-K 08 Aug 2014
Q1 2014 $18.5M 31 Mar 2014 6-K 08 Jul 2014
Q4 2013 $18.5M $0 0% 31 Dec 2013 20-F 01 Oct 2015
Q3 2013 $18.5M 30 Sep 2013 6-K 15 Jan 2014
Q2 2013 $18.5M -$1.97M -9.63% 30 Jun 2013 6-K 06 Dec 2013
Q4 2012 $18.5M +$18.5M 31 Dec 2012 20-F/A 30 Apr 2014
Q2 2012 $20.5M 30 Jun 2012 6-K 14 Dec 2012
Q1 2012 $20.5M 31 Mar 2012 6-K 13 Sep 2012
Q4 2011 $0 31 Dec 2011 20-F 30 Apr 2013
* An asterisk sign (*) next to the value indicates that the value is likely invalid.